implant analog model: ia3 ia4 cianp
"tehno dental" doo podgorica - dentalna medicinska sredstva
prestige light
"tehno dental" doo podgorica - dentalna medicinska sredstva
fermin
"dental depot cg" doo budva - dentalna medicinska sredstva
transfer models: dht33; dht34; dht35; dht44; dht45; dht46; hlt33; hlt34; hlt35; hlt44; hlt45; hlt46; actdt actit cdtnp31; cdtnp33; cdtnp34; cdtnp41; cdtnp43; cdtnp44; citnp31; citnp33; citnp34; citnp41; citnp43; citnp44
"tehno dental" doo podgorica - dentalna medicinska sredstva
sisaljka za slinu
dental grupa d.o.o., umag - sisaljke za slinu, razne, u stomatologiji
ah 26, ah plus, ah plus jet, aquasil, blueprint, ceram x, conditioner 36, dycal, kalsogen, peripac, prime&bond, smart cem, s
sljeme dental d.o.o., zagreb - u stomatologiji, kompozitni materijal i sredstva za jetkanje
plemenite dentalne legure - degulor m, biobond iii, biobond iv, biobond sg iv, degudent h, degudent ltg, degudent u, stabilor iv
pandent d.o.o., zagreb - dentalne legure za izradu krunica i mostova i kao skelet za izradu keramičkih dentalnih protetskih radova
ergonom-x
"tehno dental" doo podgorica - dentalna medicinska sredstva
iscover
sanofi winthrop industrie - klopidogrel - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - sekundarne prevencije атеротромботических eventsclopidogrel prikazan:odrasli pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija. odraslih pacijenata oboljelih od akutne коронарным sindroma:bez elevacije segmenta st akutna koronarna sindrom (nestabilna angina, ili ne-q-инфарктом miokarda), uključujući i bolesnike koji su patili ugradnje stenta nakon чрескожного koronarne intervencije, u kombinaciji s ацетилсалициловой kiselinom (ask). st segment elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции fibrillationin odraslih pacijenata s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje антагонистами vitamina k (ВКА) i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.
plavix
sanofi winthrop industrie - klopidogrel hidrogensulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции fibrillationin odraslih pacijenata s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje vitamin-k-antagonisti i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.